NexaGen Statement Regarding Recent Security Incident and Document Release
METRO CITY, May 10, 2045 — NexaGen Pharmaceuticals today issued the following statement in response to the unauthorized breach of our Innovation Drive research campus and the subsequent release of internal documents:
Early this morning, NexaGen's research facility experienced a sophisticated security breach. We are cooperating fully with law enforcement and federal authorities investigating this criminal intrusion. We are deeply concerned about the theft of proprietary research materials and controlled compounds, and we urge anyone with information to contact the FBI's Metro City field office.
Regarding the documents circulating online, NexaGen takes all allegations of regulatory non-compliance extremely seriously. We have engaged independent counsel to conduct a thorough internal review of the claims being made. While we cannot comment on ongoing legal matters or authenticate materials obtained through criminal activity, we are committed to transparency and accountability.
Effective immediately, CEO Richard Holt and Chief Science Officer Amanda Cross have stepped down from their positions to allow the company to conduct its review without distraction. The Board of Directors has appointed Dr. Margaret Chen, a 30-year pharmaceutical industry veteran, as Interim CEO.
Patient safety remains NexaGen's paramount concern. Our medications undergo rigorous testing and meet all FDA requirements. Patients currently taking Serenix® or any NexaGen therapeutic should continue their prescribed treatment regimen and consult their healthcare provider with any questions.
We understand this is a difficult moment for our patients, employees, and shareholders. NexaGen has served millions of patients since our founding in 2028, and we remain committed to the highest standards of scientific integrity and ethical conduct. We will share additional information as our review progresses.
For media inquiries, please contact our communications office.